Vanguard Asset Management
NRIX icon

Vanguard Asset Management’s Nurix Therapeutics NRIX Stock Holding History

Vanguard Asset Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07M Sell
44,173
-2,391
-5% -$40.7K ﹤0.01% 1842
2026
Q1 		$722K Buy
+46,564
New +$772K ﹤0.01% 1927

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Vanguard Asset Management's NRIX Position: Q2 2026 in Review

Vanguard Asset Management reduced its Nurix Therapeutics (NRIX) stake by 5.1% in Q2 2026, selling an estimated $40.7K and leaving 44,173 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #1842.

Vanguard Asset Management first reported a position in NRIX in Q1 2026 and has held it in 2 quarters since. 194 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Vanguard Asset Management held 44,173 shares of Nurix Therapeutics worth $1.07M as of Q2 2026.
  • Vanguard Asset Management sold 2,391 Nurix Therapeutics shares in Q2 2026, an estimated $40.7K.
  • Nurix Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #1842 holding.
  • Vanguard Asset Management first reported a position in Nurix Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 194 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.